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Prosurvival protein BCL-2 is overexpressed in estrogen receptor positive (ER+) breast cancer. In this issue of
Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the
response of xenografts from primary ER+ breast tumors to endocrine therapy and reduces tamoxifen-
induced endometrial hyperplasia, a strategy with potential clinical applicability.In this issue of Cancer Cell, encouraging
data are presented on a new approach
to enhancing the efficacy of endocrine
treatment in estrogen receptor-positive
(ER+) breast cancer by negating the
antiapoptotic properties of BCL-2 by
the use of BH3 mimetics (Vaillant et al.,
2013).
Breast cancer is the most common
invasive malignant disease in women.
Approximately 80% of breast cancer pa-
tients at primary diagnosis present with
tumors that are ER+. Estrogen mediates
its effects by binding to the ER. Estro-
gen-bound ER associates classically
with estrogen response elements on
target genes controlling proliferation and
cell survival (Ali and Coombes, 2002).
Gene expression profiling has revealed a
high degree of molecular heterogeneity
in ER+ breast cancer, which is associated
with variable clinical outcomes (Sørlie
et al., 2001). Based on gene expression
profiles, ER+ breast cancer is classified
into two groups: luminal A and luminal B.
Luminal A tumors are characterized by a
greater expression of estrogen-regulated
genes and markers associated with
luminal breast epithelial cells, whereas
these features are less apparent in luminal
B tumors, which have a greater expres-sion of proliferation-associated genes
and poorer prognosis.
Almost all patients with ER+ breast can-
cer are treated for at least 5 years with
endocrine therapy, which aims to deprive
the cancer of estrogenic signaling either
by competitive antagonistic binding of
antiestrogens (e.g., tamoxifen or fulves-
trant) or by suppressing estrogen synthe-
sis (using GnRH agonists in premeno-
pausal patients and using aromatase
inhibitors in postmenopausal patients)
(Dowsett and Howell, 2002). Such treat-
ment radically reduces the chances of
disease recurrence and death from breast
cancer. However, the beneficial effects of
endocrine treatment are attenuated in
some tumors by their ability to circumvent
the need for steroid hormones, while, in
most cases, retaining the nuclear steroid
receptors (Ali and Coombes, 2002). The
identification of the factors and pathways
responsible for the development of these
resistant conditions remains paramount
for the design of new diagnostics and
therapeutic regimens.
Tumor regressions resulting from
endocrine therapies are generally rela-
tively slow and are driven primarily by a
reduction in cell proliferation but not
increased apoptosis (Dowsett et al.,2005). Apoptosis is a highly regulated
process responsible for the removal of
damaged and unnecessary cells. The
dynamic interplay between pro-death
proteins (BAX, BAK, BAD, BIM, NOXA,
and PUMA) and pro-survival proteins
(BCL-2, BCL-XL, and BCL-W) controls
this programmed cell death (Chipuk
et al., 2010) (Figure 1). Shifting the bal-
ance between these opposing proteins
may allow the therapist to selectively
enhance apoptosis in malignant cells.
The tumorigenic potential of the over-
expression of BCL-2 was first described
as a result of the chromosomal transloca-
tion seen in subsets of non-Hodgkin’s
lymphoma, where it has been found to
be pathognomic and associated with
adverse outcome. Enhanced expression
of BCL-2 has been identified in other
malignancies, including breast cancer,
where its pathological function is less
clear. Notably, in breast cancer, BCL-2
is expressed almost exclusively in ER+
disease, where it is a favorable prognostic
factor. However, there is a ‘‘disconnect’’
in this regard between BCL-2 protein
and transcript, with the prognostic sig-
nificance of BCL-2 transcript levels
being very different from those of protein
levels. Although BCL-2 has prognosticCell 24, July 8, 2013 ª2013 Elsevier Inc. 7
Figure 1. Interplay between ER Signaling and Apoptosis
Estrogen receptor (ER) is regulated by estrogen binding and phosphorylation by a number of signal transduction kinases, including AKT. The activated ER di-
merizes and binds classically to estrogen response elements on target genes controlling proliferation and survival. The gene encoding the antiapoptotic protein
BCL-2 is an estrogen-regulated gene. Tamoxifen competes with estrogen for the ER and suppresses transcription by inducing the recruitment of corepressors as
opposed to coactivators, leading to a reduction in cell proliferation. Apoptosis is driven by a complex interplay between proapoptotic and antiapoptotic proteins.
BAX/BAK induce apoptosis by forming pores in the outer membrane of themitochondria (mitochondrial apoptosis-induced channel [MAC]), leading to the release
of cytochrome c, which activates the cytoplasmic caspase cascade. BCL-2 and BCL-XL are antiapoptotic proteins that block BAX/BAK activity. The antiapop-
totic function of BCL-2 and BCL-XL are held in check by BIM/BAD. Both BIM and BAD can form heterodimers with BCL-2, thus releasing BAX. BAD is a phos-
phorylation target of AKT. When phosphorylated, it is inactivated, releasing BCL-2 to inhibit BAX. This interplay has been exploited by the development of BH3
mimetics, which models the interaction between BCL-2 and BIM/BAD, leading to the release of BAX and induction of apoptosis.
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Previewssignificance, its role as a predictive
marker or therapeutic target is not well
defined in breast cancer (Lindeman and
Visvader, 2013). Nonetheless, the un-
doubted role of BCL-2 in restricting
apoptosis and its widespread expression
in breast cancer has attracted interest as
a therapeutic target for many years. For
example, Teixeira et al. (1995) reported
that MCF7 human ER+ breast cancer cells
had increased sensitivity to the cytotoxic
agent doxorubicin when treated with anti-
sense BCL-2. More recently, a number of
BH3 mimetic small molecules, which
mimic the action of proapoptotic BH3-
only proteins, have been developed to
counteract antiapoptotic proteins such
as BCL-2 and BCL-2-related proteins
BCL-XL and BCL-W (Souers et al.,
2013). The new anti-BCL-2 agent, ABT-8 Cancer Cell 24, July 8, 2013 ª2013 Elsevie199, used in the study by Vaillant et al.
(2013) is in Phase 1 clinical trial in patients
with non-Hodgkin’s lymphoma and
chronic lymphoid leukemia.
Vaillant et al. (2013) investigated the
BH3 mimetic ABT-737 and its platelet-
sparing analog ABT-199 alone or in com-
bination with tamoxifen in three ER+
(luminal B) and one ER patient-derived
xenograft models. All four models ex-
pressed high levels of BCL-2 but had
divergent levels of other BCL-2 family
members. Neither of the drugs alone had
a substantial impact on tumor growth,
suggesting that BCL-2-related antiapop-
totic effects had little importance in the
progression of these tumors. However,
both drugs in combination with tamoxifen
showed greater efficacy than tamoxifen
alone at reducing tumor burden and ex-r Inc.tending animal survival. In one model,
complete tumor regression was noted
with the combinations, but it was evident
that tamoxifen alone led to near complete
responses and survival of 40% of the
animal hosts. With the other two ER+
models, substantial restriction of tumor
growth occurred, but it was clear that pro-
gression occurred nonetheless. It is
notable that treatment effects with BCL-
2-specific ABT-199 in combination with
tamoxifen were similar to those with
ABT-737, which inhibits both BCL-2 and
BCL-XL, in combination with tamoxifen,
indicating BCL-2 and not BCL-XL may
be the key target in vivo.
The use of patient-derived xenografts
enhances the clinical relevance of this
work, but these only represent the four
patient tumors from which they were
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Previewsderived. The nonresponse of the ER and
ER+ tumors when treated with the BH-3
mimetics alone indicates these agents
are less likely to be effective in tumors
that show de novo resistance
to endocrine therapy, which might, for
example, depend on ER-independent
mechanisms. Rather, they would be ex-
pected to extend the speed, degree, and
duration of the response of those tumors
that are at least partially responsive.
Although it would have been reassuring
to see a similar enhancement of response
to estrogen deprivation with the BH3
mimetics, and this could have been
achieved by using low-dose estrogen
pellets, there is no compelling reason to
believe that the effects would be tamox-
ifen specific. Nonetheless, the authors
made one observation that was both
interesting and potentially helpful that is
specific to tamoxifen: ABT-737 counter-
acted tamoxifen-induced endometrial
hyperplasia, which was associated with
a profound increase in apoptotic activity
and cleaved caspase-3 positive cells,
suggesting the effects of tamoxifen in
inducing this deleterious effect may relate
to BCL-2.
In the two ER+ breast cancer models
used by Vaillant et al. (2013) that exhibited
only a partial response to the BH3-mi-metics plus tamoxifen, increased expres-
sion of phosphorylated AKT was evident.
The PI3K/AKT/mTOR pathway is
frequently activated in breast cancer (Pol-
yak and Metzger Filho, 2012) and strongly
associated with the ligand-independent
activation of ER (Ali and Coombes, 2002)
and resistance to endocrine therapy.
Furthermore, AKT modulates phosphory-
lation of BAD, suppressing its proapopto-
tic function. Asmight be expected, target-
ing the xenografts with a dual PI3K/mTOR
inhibitor in combination with ABT-737 and
tamoxifen proved superior to the mono or
dual therapies. Thus, although the
concern is expressed above that endo-
crine resistant tumors are likely to prove
resistant to combination with anti-BCL-2
agents, this might not be the case if the
mechanism of that resistance was itself
also targeted.
Lastly, in the clinic, ER+ tumors have
been found to show a reduced likelihood
of complete pathological eradication
with chemotherapy or anti-HER2 thera-
pies than ER tumors. The antagonism
of BCL-2 in these ER+ tumors might
enhance the effectiveness of these pre-
dominately proapoptotic treatments
even more than it does in these encour-
aging data from combination with endo-
crine therapies.CancerREFERENCES
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Tumor metastasis is the primary cause of death due to cancer, but the mechanisms by which tumor cells
metastasize remain incompletely understood. In this issue of Cancer Cell, Schumacher and colleagues sug-
gest that ATP released from tumor-associated platelets in the blood facilitates tumor metastasis by relaxing
endothelial barrier function.Just as countries need to protect their
borders for the purposes of national secu-
rity, so too must tissues maintain properborders for normal function. During
metastasis, tissue borders are breached
as cancer cells move from their place oforigin to distant organs, where their
growth may lead to tissue dysfunction.
Although most cancer patients die fromCell 24, July 8, 2013 ª2013 Elsevier Inc. 9
